In the spotlight: Nestle's Pfizer buy offers long-term baby food boost
Nestle has won through in the battle to acquire Pfizer's baby food business, securing an US$11.85bn deal that will see the world's largest infant nutrition group extend its lead in this fast-growing category. However, with a hefty price tag attached, the deal has not been warmly welcomed by investors. Katy Askew reports.
Get full access to all content, just $1 for 30 days
A Message From The Editor
just-food gives you the widest food market coverage.
Paid just-food members have unlimited access to all our exclusive content - including 14 years of archives.
I am so confident you will love complete access to our content that today I can offer you 30 days access for $1.
It’s our best ever membership offer – just for you.
Dean Best, editor of just-food
- How Windsor buy is part of Ajinomoto's global push
- Dairy in India: No quick win for multinationals
- Focus: Fonterra's bid to weather dairy volatility
- Dairy in India: How to win over Indian consumers
- On the money: Diamond's faith in on-trend range
- Nestle forms new unit to "leverage scale"
- Nestle sells baby food brands Alete, Milasan
- Kerry, Premier team up on frozen NPD in UK
- General Mills to slash up to 800 more jobs
- PepsiCo eyes Middle East growth with R&D centre